SpineEx withdrew its plans for an initial public offering late in 4Q18. It originally filed in late 3Q18 with a proposed deal size of US $17MM.
The original registration statement was not declared effective, and no shares of common stock or other securities were sold under the registration statement. SpineEx requested that all fees paid to the SEC in connection with the filing be credited to the company’s account as an offset of all or a portion of fees for a subsequent filing.
The company has developed the Sagittae® expandable and adjustable cage for lateral lumbar fusion, which received FDA 510(k) clearance in 4Q18.
SpineEx withdrew its plans for an initial public offering late in 4Q18. It originally filed in late 3Q18 with a proposed deal size of US $17MM.
The original registration statement was not declared effective, and no shares of common stock or other securities were sold under the registration statement. SpineEx requested that all fees paid to the...
SpineEx withdrew its plans for an initial public offering late in 4Q18. It originally filed in late 3Q18 with a proposed deal size of US $17MM.
The original registration statement was not declared effective, and no shares of common stock or other securities were sold under the registration statement. SpineEx requested that all fees paid to the SEC in connection with the filing be credited to the company’s account as an offset of all or a portion of fees for a subsequent filing.
The company has developed the Sagittae® expandable and adjustable cage for lateral lumbar fusion, which received FDA 510(k) clearance in 4Q18.
Copy to clipboard 
